6 March 2019: Quanta Dialysis Technologies Ltd, a pioneering British medical technology company developing a personal haemodialysis system (SC+) for patient use in the clinic and the home, today announces that the Company will be presenting at the 39th Annual Dialysis Conference (ADC), which runs from 16 to 19 March 2019, at the Sheraton Dallas Hotel, Texas, USA.

Dr. Paul Komenda, Chief Medical Officer, will provide an update on SC+, explaining how it enables choice, efficiency and empowerment to both patients and physicians in the “Home Dialysis Machines” session on Monday, 18 March at 3:00pm. The presentation will be followed by a device demonstration at 3:45pm.

Full details of the session are as follows

Session: Home Dialysis Machines
Date: Monday 18 March
Time: 3:00pm
Location: 04H

If you would like to arrange a meeting with John E. Milad, Chief Executive Officer or Paul Komenda, Chief Medical Officer, at the conference, please contact enquiries@quantadt.com.

25 February 2019: Quanta Dialysis Technologies Ltd, a pioneering British medical technology company developing a personal haemodialysis system (SC+) for patient use in the clinic and the home, today announces the expansion of its management team with the appointment of Steve Lane as Commercial Director, Chanel Allen-Megahey as Global Quality Assurance and Regulatory Affairs Director and Frank Herrmann as Marketing Director.

Steve is an experienced leader in medical devices, with a significant track record of building successful businesses and launching novel therapy solutions. He joins Quanta from Orthogem, where he served as Chief Executive Officer. Prior to that, Steve held various roles including Director of Business Model Innovation in Western Europe and Head of Homecare at Baxter Healthcare Ltd. Steve holds a BA (Hons) in Economics from the University of Middlesex and an MBA from the Cranfield School of Management.

Chanel is an experienced quality and regulatory professional with specific experience working with medical devices, equipment and start-up companies. Before joining Quanta, Chanel was an independent Quality and Regulatory Consultant at DRCAM Solutions. She has over 20 years’ experience assisting emerging and established medical device companies, including HeartSine Technologies, TG Eakin, Pelican Healthcare, Trivirix International amongst many others. Chanel holds a BSc (Hons) in Biological Science, as well as a PhD in Applied Plant Pathology with Molecular Microbiology, from Queen’s University of Belfast.

Frank has 23 years’ international medical marketing experience, with a focus on home therapies in oncology, cystic fibrosis and nephrology. Frank has held various senior marketing positions at Fresenius and Baxter Healthcare in Germany, Australia and the UK. During his eight years at Baxter, Frank drove key projects promoting the acceptance of home dialysis and was the D/A/CH lead for the international workgroup developing the VIVIA home haemodialysis device.

John E. Milad, Chief Executive Officer of Quanta, commented on the appointments: “I am delighted and honoured to welcome Steve, Chanel and Frank to Quanta’s leadership team. We have an exciting year ahead of us with the planned commercial launch of our personal haemodialysis system, SC+. The experience these talented professionals bring with them, specifically in relation to launching new medical devices and home therapies, will be invaluable as we continue our journey towards commercialisation and, ultimately, for achieving our mission to improve the lives of dialysis patients.”

4 January 2019: Quanta Dialysis Technologies Ltd, a medical device company providing innovative haemodialysis solutions for clinic and home settings, today announces that the Company has appointed Dr. Paul Komenda as Chief Medical Officer. Dr. Komenda, Associate Professor of Medicine at the University of Manitoba, is a fellow of the American Society of Nephrology and has extensive clinical and academic experience.

Dr. Komenda previously served on the Scientific Advisory Board of NxStage Medical. He gained his medical qualification in 2001 from the University of Manitoba and is a board certified Nephrologist. Dr. Komenda studied health economics at the University of Calgary, holds a Masters in Health Administration and is also the Medical Director of the Home Dialysis Program and the Seven Oaks General Hospital in Manitoba.

Dr. Komenda has over 130 published peer reviewed articles in health services research and clinical nephrology and, with a specialist knowledge and interest in the field of home dialysis and health economics, Dr. Komenda is highly regarded as an expert in his field.

John E. Milad, Chief Executive Officer of Quanta, commented on the appointment: “We are excited to have Dr. Komenda join Quanta as our Chief Medical Officer. He brings a wealth of knowledge and expertise as a respected global thought-leader with extensive clinical experience in home dialysis. He will be invaluable to Quanta’s future success as we prepare to launch our innovative personal haemodialysis system, SC+, later this year in Europe.”

The Plastics Industry Awards 2018

1 October 2018: Quanta Dialysis Technologies Ltd, a British medical device company pioneering innovative haemodialysis products for dialysis patients, is pleased to announce that it has won the “Industrial Product Design of the Year” award at the Plastics Industry Awards 2018.

John E. Milad, Chief Executive Officer of Quanta, said: “I am delighted that Quanta and the design of SC+ have been recognised by a group of industry experts through this award. Assisted by Smallfry, an industrial design consultancy, the team at Quanta has worked tirelessly to hone our innovative personal haemodialysis system, SC+. We are proud of our patient-friendly, easy to use system that can support patients across the continuum of care, from the clinic to the home. This award is testament to all their hard work and efforts, and we would like to dedicate it to all the engineers and designers whose enthusiasm made this development possible.”

The design of the SC+ haemodialysis system focuses on providing an intuitive user experience, centring on a large, interactive graphical touchscreen that guides users through a treatment via logical steps. This intuitive, tablet-style approach, combined with ergonomic
industrial design, is intended to provide patients with a simple yet powerful platform for managing their treatments around their lives. Furthermore, every detail of the user experience and product design is streamlined to provide maximum safety and ease of use. The small
footprint and modern design of the SC+ machine blends unobtrusively into different environments, expanding the range of treatment options available to patients.

Now in its 18th year, the Plastics Industry Awards is firmly established as the forum for recognising excellence in an increasingly competitive market. Launched in 2001 and held annually in London, this event is dedicated to honouring innovation and exceptional performance. The Plastics Industry Awards acknowledge the best companies and the best people in the market.

31 August 2018: Quanta Dialysis Technologies Ltd, a medical device company providing innovative haemodialysis solutions for clinic and home settings, today announces that the Company will be exhibiting at the 11th UK Annual Dialysis Conference, taking place from Thursday 20th to Friday 21st September 2018, at the Lowry Hotel in Manchester, UK.

The UK Annual Dialysis Conference theme for 2018 is ‘Advancing Dialysis: Now and for the Future’ and will focus on clinical challenges, innovative solutions and future advances in dialysis care. Quanta will exhibit the new look of its personal haemodialysis system, SC+, which it plans to launch in 2019. SC+ is designed to give patients flexibility and to empower them to take control of their dialysis, enabling them to fit treatment around everyday life.

In addition, Quanta will be hosting a workshop on Thursday 20th September from 08:30 to 09:30am during which Professor John Agar, Clinical Conjoint Professor of Medicine at Deakin University School of Medicine and the Geelong Hospital, Barwon Health and a member of Quanta’s Medical Advisory Board will, in a presentation entitled: ‘Home Haemodialysis Down Under: Making the Most of Home Therapies’, discuss how Australia and New Zealand have managed to achieve the highest regional adoption rates for home haemodialysis and how SC+ can support the expansion of home dialysis in the UK. Following the seminar, there will be an opportunity, led by Quanta’s clinical nursing team, which will enable attendees to have a hands-on demonstration of SC+.

If you would like to register to attend the free workshop, please RSVP to David.bond@quantadt.com.

If you would like to arrange a meeting with John E. Milad, Chief Executive Officer, or Peter Hoyer, Chief Commercial Officer, at the conference, please contact enquiries@quantadt.com.

21 May 2018: Quanta Dialysis Technologies Ltd, a British medical device company providing innovative haemodialysis solutions for the clinic and the home, today announces that the Company will be exhibiting at the 55th Annual European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Congress which runs from Thursday 24th to Sunday 27th May, at the Bella Center in Copenhagen, Denmark, at booth number 4.151.

Quanta will be showcasing its new look, state-of-the-art personal haemodialysis system, SC+, designed to offer patients flexibility enabling them to fit treatment around everyday life. Quanta will also present a poster at the congress which will conclude the results of the SC+ Pilot Study, which includes extensive, successful, patient treatments at four NHS Trusts across the UK.

Full details of the poster are as follows

Date: 26 May 2018
Time: 09:30 – 10:45 and 16:30 – 17:00
Number: SP474
Title: Implementation of a compact haemodialysis system in a real-world environment: assessment of user uptake, safety, performance and usability.
Authors: Dr. Charlotte Bebb, Dr. Clara Day, Dr. Cormac Breen, Dr. Sandip Mitra, John E. Milad and James Grainger

If you would like to arrange a meeting with John E. Milad, Chief Executive Officer or Peter Hoyer, Chief Commercial Officer, at the conference, please contact enquiries@quantadt.com.

ERA-EDTA brings together worldwide physicians and kidney specialists to learn and share the latest advances in the field of clinical nephrology, dialysis, renal transplantation, and related subjects.

March 2018: Quanta Dialysis Technologies Ltd, a medical device company providing innovative haemodialysis solutions for the clinic and the home, today announces that the Company will be presenting at the 38th Annual Dialysis Conference (ADC), which runs from 3 to 6 March 2018, at the Marriott Orlando World Center in Florida, USA.

Peter Hoyer, Chief Commercial Officer, will provide an update on Quanta’s unique small, simple and powerful haemodialysis system, SC+, in the “Home HD Machines” session chaired by Robert Lockridge, MD, on Sunday 4 March at 2.15pm.

The session will include an update on the results of the SC+ Pilot Study, which includes extensive, successful, patient treatments at four NHS Trusts across the UK. In addition, and ahead of commercial launch in H2 2018, the Company will discuss the features of its state-of-the-art personal haemodialysis system designed to enable patients to fit dialysis around their lives.

Full details of the session are as follows

Session: Home HD Machines (reference: 02C)
Date: Sunday 4 March
Time: 2.15pm
Location: Grand 13-14

If you would like to arrange a meeting with John E. Milad, Chief Executive Officer or Peter Hoyer, Chief Commercial Officer, at the conference, please contact enquiries@quantadt.com.